Your session is about to expire
← Back to Search
Daratumumab Administration Methods for Multiple Myeloma
Study Summary
This trial is testing whether a new way of administering daratumumab (under the skin instead of through a vein) is just as effective as the current method.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 3 trial • 522 Patients • NCT03277105Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You are planning to have a stem cell transplant before your condition gets worse during the study.You have received at least three different types of treatment, including specific medications called proteasome inhibitors and immunomodulatory drugs, unless you had a severe allergic reaction to them early in your treatment.You have been treated with daratumumab or other medications targeting CD38 in the past.You are able to perform daily activities without any problems or with minimal restrictions due to your health.You had a stem cell transplant in the past 12 weeks, or you had a different type of stem cell transplant at any time.You have a specific level of abnormal proteins in your blood or urine that can be measured.You had cancer (except for multiple myeloma) and finished treatment at least 2 years ago with no signs of the disease. Some types of non-invasive cancers may be allowed if considered cured with low risk of coming back within 3 years.You have shown improvement, like a partial response or better, to at least one previous treatment according to the doctor's evaluation using specific criteria.Women who could become pregnant must have a negative pregnancy test within 14 days before starting the study.You have been diagnosed with multiple myeloma based on specific medical criteria.You need to meet specific medical test requirements outlined in the study plan.You have taken medication for myeloma within 2 weeks or 5 pharmacokinetic half-lives before the trial starts.
- Group 1: Dara SC
- Group 2: Dara IV
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
For what purpose is Dara SC most often employed?
"Dara SC can help patients with various conditions, such as refractory multiple myeloma or relapsed cell transplants. Additionally, it is also useful for treating biological response modifiers."
Are there any other ongoing studies that use Dara SC as a treatment?
"Currently, there are 142 Dara SC clinical trials ongoing with 26 in Phase 3. Most of these studies originate from Harrison, New york; however, 5 580 locations worldwide are running Dara SC trials."
Does Dara SC have any life-threatening side effects?
"Dara SC's safety is rated as a 3 by our team because it has reached Phase 3 in clinical trials. This suggests there is both efficacy and safety data from multiple rounds of testing."
What is the cap on how many people can join this research project?
"Though this trial was posted on October 27th, 2017 and updated November 3rd, 2022, it is not presently recruiting patients. For those interested in other studies, there are currently 826 clinical trials actively searching for patients with multiple myeloma and 142 trials for Dara SC looking for participants."
How many distinct places are in charge of this clinical trial?
"So far, this clinical trial is being conducted out of Cross Cancer Institute in Edmonton, Alberta, The Gordon & Leslie Diamond Health Care Center in Vancouver, British Columbia, and Dana-Farber Cancer Institute in Boston, Massachusetts with 9 other locations still to be determined."
Share this study with friends
Copy Link
Messenger